@article {Lai2022.07.27.22278121, author = {Jianyu Lai and Kristen K. Coleman and S.-H. Sheldon Tai and Jennifer German and Filbert Hong and Barbara Albert and Yi Esparza and Aditya K. Srikakulapu and Maria Schanz and Isabel Sierra Maldonado and Molly Oertel and Naja Fadul and T. Louie Gold and Stuart Weston and Kristin Mullins and Kathleen M. McPhaul and Matthew Frieman and Donald K. Milton}, title = {Evolution of SARS-CoV-2 Shedding in Exhaled Breath Aerosols}, elocation-id = {2022.07.27.22278121}, year = {2022}, doi = {10.1101/2022.07.27.22278121}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Aerosol inhalation is increasingly well recognized as a major if not primary mode of transmission of SARS-CoV-21,2. Over the course of the COVID-19 pandemic, three highly transmissible lineages evolved and became globally dominant3. One hypothesis to explain increased transmissibility is that natural selection favours variants with higher rates of viral aerosol shedding. However, the extent of aerosol shedding of successive SARS-CoV-2 variants is unknown. Here, we demonstrate that viral shedding (measured as RNA copies) into exhaled breath aerosol was significantly greater during infections with Alpha, Delta, and Omicron than with ancestral strains and variants not associated with increased transmissibility. The three highly transmissible variants independently evolved a high viral aerosol shedding phenotype, demonstrating convergent evolution. We did not observe statistically significant differences in rates of shedding between Alpha, Delta, and Omicron infections. The highest shedder in our study, however, had an Omicron infection and shed three orders of magnitude more viral RNA copies than the maximum observed for Delta and Alpha4. Our results also show that fully vaccinated and boosted individuals, when infected, can shed infectious SARS-CoV-2 via exhaled breath aerosols. These findings provide additional evidence that inhalation of infectious aerosols is the dominant mode of transmission and emphasize the importance of ventilation, filtration, and air disinfection to mitigate the pandemic and protect vulnerable populations. We anticipate that monitoring aerosol shedding from new SARS-CoV-2 variants and emerging pathogens will be an important component of future threat assessments and will help guide interventions to prevent transmission via inhalation exposure.Competing Interest StatementThis work was supported by the Prometheus-UMD, sponsored by the Defense Advanced Research Projects Agency (DARPA) BTO under the auspices of Col. Matthew Hepburn through agreement N66001-18-2-4015, the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (CEIRS) Contract Number HHSN272201400008C, and the Centers for Disease Control and Prevention Contract Number 200-2020-09528. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position or policy of these funding agencies and no official endorsement should be inferred. This work was also supported by a grant from the Bill \& Melinda Gates Foundation, and a generous gift from The Flu Lab (https://theflulab.org). The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. D.K.M., Y.E, and B.A. received payments to their institution from Moderna, Inc., and Novavax, Inc., outside the submitted work. J.G. and M.S. received payments to their institution from Novavax, Inc., outside the submitted work. S.W. and M.F. received payments to their institution from National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA), Gates Foundation, Aikido Pharma, Emergent, Astrazeneca, Novavax, Regeneron, and the CDC, outside the submitted work. M. F. received royalties/licenses from Aikido Pharma for antiviral drug patent licensing, consulting fees from Aikido Pharma, Observatory Group, for consulting for COVID-19, and participation on Scientific Advisory Board for Aikido Pharma, outside the submitted work. None of the other authors have potential conflicting interests.Funding StatementThis work was supported by the Prometheus-UMD, sponsored by the Defense Advanced Research Projects Agency (DARPA) BTO under the auspices of Col. Matthew Hepburn through agreement N66001-18-2-4015, the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (CEIRS) Contract Number HHSN272201400008C, and the Centers for Disease Control and Prevention Contract Number 200-2020-09528. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position or policy of these funding agencies and no official endorsement should be inferred. This work was also supported by a grant from the Bill \& Melinda Gates Foundation, and a generous gift from The Flu Lab (https://theflulab.org). The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. D.K.M., Y.E, and B.A. received payments to their institution from Moderna, Inc., and Novavax, Inc., outside the submitted work. J.G. and M.S. received payments to their institution from Novavax, Inc., outside the submitted work. S.W. and M.F. received payments to their institution from National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA), Gates Foundation, Aikido Pharma, Emergent, Astrazeneca, Novavax, Regeneron, and the CDC, outside the submitted work. M. F. received royalties/licenses from Aikido Pharma for antiviral drug patent licensing, consulting fees from Aikido Pharma, Observatory Group, for consulting for COVID-19, and participation on Scientific Advisory Board for Aikido Pharma, outside the submitted work. None of the other authors have potential conflicting interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Maryland Institutional Review Board and the Human Research Protection Office of the Department of the Navy gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data for the accepted manuscript will be made available on the Open Science Framework repository.}, URL = {https://www.medrxiv.org/content/early/2022/07/29/2022.07.27.22278121}, eprint = {https://www.medrxiv.org/content/early/2022/07/29/2022.07.27.22278121.full.pdf}, journal = {medRxiv} }